Voyager Therapeutics (NASDAQ:VYGR) Stock Crosses Below 50 Day Moving Average – Here’s What Happened

Voyager Therapeutics, Inc. (NASDAQ:VYGR) shares crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $3.57 and traded as low as $3.06. Voyager Therapeutics shares last traded at $3.10, with a volume of 417,266 shares changing hands.

Analysts Set New Price Targets

A number of brokerages recently weighed in on VYGR. Truist Financial upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Wall Street Zen downgraded shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. HC Wainwright reiterated a “buy” rating on shares of Voyager Therapeutics in a research note on Monday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Voyager Therapeutics in a report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $16.50.

Voyager Therapeutics Stock Performance

The company’s 50-day moving average price is $3.57 and its 200 day moving average price is $3.81. The stock has a market cap of $187.30 million, a PE ratio of -1.57 and a beta of 1.27.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. Voyager Therapeutics had a negative net margin of 319.61% and a negative return on equity of 55.97%. The company had revenue of $1.19 million for the quarter, compared to the consensus estimate of $8.79 million. On average, sell-side analysts anticipate that Voyager Therapeutics, Inc. will post -1.43 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Voyager Therapeutics

A number of hedge funds have recently modified their holdings of VYGR. Wexford Capital LP bought a new position in shares of Voyager Therapeutics during the third quarter worth $42,000. ProShare Advisors LLC bought a new stake in Voyager Therapeutics in the 4th quarter valued at $44,000. CIBC Asset Management Inc purchased a new stake in Voyager Therapeutics in the 4th quarter worth $45,000. Coldstream Capital Management Inc. purchased a new stake in Voyager Therapeutics in the 3rd quarter worth $55,000. Finally, Caitong International Asset Management Co. Ltd lifted its stake in Voyager Therapeutics by 42,410.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 15,729 shares of the company’s stock worth $62,000 after purchasing an additional 15,692 shares in the last quarter. 48.03% of the stock is currently owned by institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.